Cytokinetics Inc vs Clear Secure Inc — how do they compare? Cytokinetics Inc trades at $82.14 (market cap $11.12B), while Clear Secure Inc trades at $54.15 (market cap $5.39B). The key difference: Cytokinetics Inc is far larger — about 2.1× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.12% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | YOU | |
|---|---|---|
Market Cap | $11.12B | $5.39B |
Sector | Technology | Technology |
52-Week High | $87.26 | $62.36 |
52-Week Low | $33.23 | $28.84 |
Enterprise Value | $11.59B | $4.71B |
Dividend Yield | — | 1.12% |
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Clear Secure (YOU) trades at $53.08, down 3.88% on the day, with technical indicators showing bearish momentum. The company demonstrates strong fundamentals with 65.48% gross margins and impressive 81.15% ROE. Recent Q1 2026 earnings beat expectations at $0.38 EPS versus $0.35 expected, while analysts maintain a mixed consensus with 44% buy ratings and a $56.67 price target. The company continues expanding its airport security services with recent launches in Indianapolis and Miami.
YOU presents a compelling growth story with expanding revenue and profitability, though elevated valuation multiples (P/E 42.83) warrant caution. Near-term catalysts include Q2 earnings and continued airport expansion, while risks involve execution challenges and market volatility. The stock offers potential upside to analyst targets but requires monitoring of earnings consistency.
Trailing returns across standard periods
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →